FdaApplication
NDA 217779
Identifiers
- fda_app_no: NDA217779
Properties
| Property | Value |
|---|---|
| applicant_name | GERON CORP |
| application_type | NDA |
| approval_date | 2024-06-06 |
Revenue by product
RYTELO
| Period | Revenue |
|---|---|
| Q1 2024 | $0.3M† |
| Q4 2023 | $0.0M† |
| Q3 2023 | $0.2M† |
| Q1 2023 | $0.0M† |
| Q4 2022 | $0.1M† |
| Q3 2022 | $0.3M† |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one. A figure marked † is the company's one reported revenue line rather than a product breakdown.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| RYTELO | IMETELSTAT SODIUM | EQ 188MG BASE/VIAL | POWDER;INTRAVENOUS |
| RYTELO | IMETELSTAT SODIUM | EQ 47MG BASE/VIAL | POWDER;INTRAVENOUS |
2 products